“NAMI was founded by parents of adult children with schizophrenia over 40 years ago and we’re proud to be a part of the of the Accelerating Medicines Partnership for Schizophrenia, a watershed moment in our field,” said Daniel H. Gillison, Jr., CEO of NAMI. “This partnership is a new opportunity for coordinated research on the root causes and progression of schizophrenia, a complex, long-term medical illness. NAMI is dedicated to this partnership which represents the best of the public, private and academic communities. We can all agree that we need better treatments for psychosis and this partnership has the potential to fast-track progress in this area.”
